Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide

Chemotherapy

Volumn 58, Issue 6, 2013, Pages 461-467

  Wen, Hong Sheng ^a   Li, Xu ^a   Cao, Yu Zhu ^a   Zhang, Cui Cui ^a   Yang, Fang ^a   Shi, Yu Ming ^a   Peng, Li Ming ^a  

^a Oncology and Hematology Department   (China)

Author keywords

Cancer related anorexia cachexia syndrome; Megestrol acetate; Thalidomide

Indexed keywords

INTERLEUKIN 6; MEGESTROL ACETATE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; APPETITE; ARTICLE; BODY WEIGHT; CACHEXIA; CANCER CHEMOTHERAPY; CLINICAL STUDY; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; GRIP STRENGTH; HUMAN; MAJOR CLINICAL STUDY; MALE; PERFORMANCE MEASUREMENT SYSTEM; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; THROMBOEMBOLISM; TREATMENT DURATION;

AGED; APPETITE STIMULANTS; BODY WEIGHT; CACHEXIA; DRUG THERAPY, COMBINATION; FATIGUE; FEMALE; HAND STRENGTH; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; MALE; MEGESTROL ACETATE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; QUALITY OF LIFE; THALIDOMIDE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873584731     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000346446     Document Type: Article

References (34)

1. Tazi E, Errihani H: Treatment of cachexia in oncology. Indian J Palliat Care 2010; 16: 129-137.
2. Neumann F: The physiological action of progesterone and the pharmacological effects of progestogens - a short review. Postgrad Med J 1978;54: 11-24.
3. Becker KL: Principles and Practice of Endocrinology and Metabolism. New York, Lippincott, Williams and Wilkins, 2001.
4. Mantovani G, Maccio A, Massa E, Madeddu C: Managing cancer-related anorexia/cachexia. Drugs 2001; 61: 499-514.
5. Argiles JM, Lopez-Soriano FJ, Busquets S: Counteracting inflammation: a promising therapy in cachexia. Crit Rev Oncog 2012; 17: 253-262.
6. Jazieh AR, Komrokji R, Gupta A, Patil S, Flora D, Knapp M, Issa M, Abdel Karim N: Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer. Cancer Invest 2009; 27: 932-936.
7. Ott PA, Chang JL, Oratz R, Jones A, Farrell K, Muggia F, Pavlick AC: Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma. Chemotherapy 2009; 55: 221-227.
8. Teo SK, Stirling DI, Zeldis JB: Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov Today 2005; 10: 107-114.
9. Reid J, Mills M, Cantwell M, Cardwell CR, Murray LJ, Donnelly M: Thalidomide for managing cancer cachexia. Cochrane Database Syst Rev 2012; 4:CD008664.
10. Davis M, Lasheen W, Walsh D, Mahmoud F, Bicanovsky L, Lagman R: A phase II dose titration study of thalidomide for cancer-associated anorexia. J Pain Symptom Manag 2012; 43: 78-86.
11. Prue G, Rankin J, Cramp F, Allen J, Gracey J: Fatigue in gynaecological cancer patients: a pilot study. Support Care Cancer 2006; 14: 78-836.
12. Masika GM, Wettergren L, Kohi TW, von Essen L: Health-related quality of life and needs of care and support of adult Tanzanians with cancer: a mixed-methods study. Health Qual Life Outcomes 2012; 10: 133.
13. McMillan DC: An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc 2008; 67: 257-262.
14. Madeddu CMaccio A, Panzone F, Tanca FM, Mantovani G: Medroxyprogesterone acetate in the management of cancer cachexia. Expert Opin Pharmacother 2009; 10: 1359-1366.
15. Mantovani G, Maccio ALai P, Massa E, Ghiani M, Santona MC: Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. Crit Rev Oncog 1998; 9: 99-106.
16. Mantovani G, Maccio A, Lai P, Massa E, Ghiani M, Santona MC: Cytokine activity in cancer- related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol 1998; 25: 45-52.
17. Argiles JM, Lopez-Soriano FJ, Busquets S: Counteracting inflammation: a promising therapy in cachexia. Crit Rev Oncog 2012; 17: 253-262.
18. Kim HJ, Kim HJ, Yun J, Kim KH, Kim SH, Lee SC Bae SB, Kim CK, Lee NS, Lee KT,Park SK, Won JH, Park HS, Hong DS. Pathophysiological role of hormones and cytokines in cancer cachexia. J Korean Med Sci 2012;27: 128-134.
19. McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS: Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 2001; 41: 64-69.
20. Partridge M, Fallon M, Bray C, McMillan D, Brown D, Laird B: Prognostication in advanced cancer: a study examining an inflammation- based score. J Pain Symptom Manage 2012; 44: 161-167.
21. El-Mowafy AM, El-Mesery ME, Salem HA, Al-Gayyar MM, Darweish MM: Prominent chemopreventive and chemoenhancing effects for resveratrol: unraveling molecular targets and the role of C-reactive protein. Chemotherapy 2010; 56: 60-65.
22. Shimoda M, Katoh M, Kita J, Sawada T, Kubota K: The Glasgow Prognostic Score is a good predictor of treatment outcome in patients with unresectable pancreatic cancer. Chemotherapy 2010; 56: 501-506.
23. Mantovani G, Maccio A, Esu S, Lai P, Santona MC, Massa E, Dessi D, Melis G, Del Giacco S: Medroxyprogesterone acetate reduces the production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Biochem Soc Trans 1997; 25: 296.
24. Yeh SS, Schuster MW: Megestrol acetate in cachexia and anorexia. Int J Nanomed 2006; 1: 411-416.
25. Tomiska M, Tomiskova M, Salajka F, Adam Z, Vorlicek J: Palliative treatment of cancer anorexia with oral suspension of megestrol acetate. Neoplasma 2003; 50: 227-233.
26. De Conno F, Martini C, Zecca E, Balzarini A, Venturino P, Groff L, Caraceni A: Megestrol acetate for anorexia in patients with far-advanced cancer: a double-blind controlled clinical trial. Eur J Cancer 1998; 34 1705-1709.
27. Maccio A, Madeddu C, Gramignano G, Mulas C, Floris C, Sanna E, Cau MC, Panzone F, Mantovani G: A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol 2012; 124: 417-425.
28. Berenstein EG, Ortiz Z: Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2005:CD004310.
29. Davis M, Lasheen W, Walsh D, Mahmoud F, Bicanovsky L, Lagman R: A phase II dose titration study of thalidomide for cancer-associated anorexia. J Pain Symptom Manage 2012; 43: 78-86.
30. Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM: Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005; 54: 540-545.
31. Mantovani G, Maccio A, Madeddu C, Gramignano G, Serpe R, Massa E, Dessi M, Tanca FM, Sanna E, Deiana L, Panzone F, Contu P, Floris C: Clinical trial with thalidomide in patients with tumors at different sites in progression of disease after previous treatments. Support Palliat Cancer Care 2004; 1: 21-28.
32. Madeddu C, Dessi M, Panzone F, Serpe R, Antoni G, Cau MC, Montaldo L, Mela Q, Mura M, Astara G, Tanca FM, Maccio A, Mantovani G: Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia-cachexia syndrome. Clin Nutr 2012; 31: 176-182.
33. van der Meij BS, Schoonbeek CP, Smit EF, Muscaritoli M, van Leeuwen PA, Langius JA: Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensusbased frameworks. Br J Nutr 2012; 16: 1-9.
34. Coronha AL, Camilo ME, Ravasco P: The relevance of body composition in cancer patients: what is the evidence? Acta Med Port 2011; 24: 769-778.